Yuki Muroyama, MD, PhD, on A Novel Marker of Clinical Response to PD-1 Blockade Under Study
Yuki Muroyama, MD, PhD, of the University of Pennsylvania Perelman School of Medicine, discusses the interaction between the immune system and a novel marker—T-cell DNA damage and repair response—to understand how that interaction may affect immune cell biology and therapeutic response (Abstract 310).
Jeffrey Weber, MD, PhD, of NYU Langone Medical Center, offers his perspective on the impact of the COVID-19 pandemic on oncology care and cancer clinical trials, as clinicians strive to provide optimal treatment to patients while reducing their risk of contracting the coronavirus. The steep decline in trial enrollment has recovered, with many of the changes in how research was conducted as a result of the pandemic still in place and improving the process going forward.
Patrick Hwu, MD, of Moffitt Cancer Center and President of the Society for Immunotherapy of Cancer (SITC), and Mary Dean, JD, CAE, SITC Executive Director, discuss the organization’s mission, strides made in cancer immunology, meeting the challenge of immunoresistance, and the new SITC app for clinical practice guidelines. This app places a useful tool in the hands of health-care providers, one that can be continually updated as the science evolves.
Sean Khozin, MD, MPH, of CancerLinQ, discusses the therapeutic advances that have made cancer care more targeted, even as real-world patient outcomes lag behind those reported in clinical trials. Dr. Khozin makes the case for the use of digital decision support tools to advance precision at the point of care.
Stephanie T. Schmidt, PhD, of The University of Texas MD Anderson Cancer Center, discusses the first integrated examination of the immunomodulatory effects of neoadjuvant chemotherapy, nivolumab, and nivolumab plus chemotherapy in resected non–small cell lung cancer (Abstract 962).
Mehmet Altan, MD, of The University of Texas MD Anderson Cancer Center, discusses findings from a phase Ib dose-escalation study, which showed early evidence of activity for NKTR-255, an investigational IL-15 receptor agonist, plus cetuximab in patients with solid tumors. Treatment appeared to lead to expansion and proliferation of NK and CD8+ cells (Abstract 957).